<P>&nbsp;</P> <P align=justify><STRONG><STRONG><A title="" href="https://www.aderly.com/lyon-economic-news/news-NEW-PARTNERSHIPS-FOR-GENOWAY,n,4472,EN.jsp" target=_blank>genOway is a company based in Lyon</A></STRONG> and specialized in innovative animal models</STRONG>. The company has recently <STRONG>signed a contract with Bluebird Bio, a European biologics company for RMCE</STRONG> (Recombinase-Mediated Cassette Exchange) technology-based genetically modified rodents.</P> <P align=justify>&nbsp;</P> <P align=justify>Bluebird Bio has granted genOway an <STRONG>exclusive worldwide license for the use of RMCE technology in the field of genetically modified rodents.</STRONG></P> <P align=justify>&nbsp;</P> <P align=justify>The development of biologics technologies such as therapeutic antibodies requires the use of appropriate pre-clinical models at each step: target validation, antibody development, affinity and specificity evaluation toward the humanized target, efficacy and safety studies. </P> <P align=justify>&nbsp;</P> <P align=justify>According to genOway, this partnership &#8220;<EM>is a new proof of the quality and relevance of our technologies</EM>.&#8221;</P> <P>&nbsp;</P>